A breakthrough advancement in neuromodulation
Cognito was founded in 2016 based on experiments conducted by scientific founders Li-Huei Tsai and Ed Boyden at MIT. These initial experiments led to the development of our proprietary neuromodulation platform and the completion of multiple clinical studies in Alzheimer’s disease.
Our approach is a non-invasive neurostimulation that induces gamma oscillations in the brain and was designed to accommodate the specific needs of individuals with Alzheimer’s disease. Since our founding in 2016, we have completed more than 35,000 treatment sessions in multiple clinical studies to determine the effects of this novel therapy on Alzheimer’s disease.
In December 2020, we received FDA Breakthrough Device Designation and will enroll in a pivotal study before the end of 2021.
• Planned enrollment in pivotal study for Alzheimer’s disease
• Main study completion of ETUDE
• 35,000 treatment sessions
• FDA Breakthrough Device designation
• Main study completion of OVERTURE
• 25,000 treatment sessions
• Main study completion of FLICKER
• Launch of three clinical studies (ETUDE, OVERTURE, FLICKER)
• 15,000 treatment sessions
• Completion of safety and feasibility studies
• Completed development of product platform
• Cognito founding
• Initial MIT experiments conducted